Repligen Corp (RGEN)

44.40
1.70 3.60
NASDAQ : Health Care
Prev Close 46.06
Open 45.89
Day Low/High 43.99 / 45.89
52 Wk Low/High 20.07 / 39.17
Volume 260.37K
Avg Volume 340.60K
Exchange NASDAQ
Shares Outstanding 43.05M
Market Cap 1.91B
EPS 0.30
P/E Ratio 86.90
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BUFF, PRIM, QTRH, RGEN, WBT Downgrades: AGM, AHC, BHB, CLSD, EVK, GTIM, MLNX, OBCI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Repligen To Report Second Quarter 2017 Financial Results

Repligen To Report Second Quarter 2017 Financial Results

Webcast and Conference Call to Be Held Thursday, August 3, 2017 at 8:30 a.m. EDT

Short Interest In Repligen Declines 10.5%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 389,232 share decrease in total short interest for Repligen Corp. , to 3,322,230, a decrease of 10.49% since 05/31/2017.

Repligen Reaches Analyst Target Price

In recent trading, shares of Repligen Corp. have crossed above the average analyst 12-month target price of $38.80, changing hands for $38.99/share.

Repligen To Report First Quarter 2017 Financial Results

Webcast and Conference Call to Be Held Thursday, May 4, 2017 at 8:30 a.m. EDT

Repligen Reaches Analyst Target Price

In recent trading, shares of Repligen Corp. have crossed above the average analyst 12-month target price of $35.33, changing hands for $35.35/share.

Repligen To Report Fourth Quarter And Full Year 2016 Financial Results, Provides Financial Guidance For 2017

Webcast and Conference Call to Be Held Wednesday, February 22, 2017 at 8:30 a.m. EST

Notable Two Hundred Day Moving Average Cross - RGEN

Notable Two Hundred Day Moving Average Cross - RGEN

In trading on Tuesday, shares of Repligen Corp. crossed below their 200 day moving average of $29.07, changing hands as low as $28.53 per share.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

UPDATE -- Repligen Acquires TangenX Technology Corporation

UPDATE -- Repligen Acquires TangenX Technology Corporation

Adds innovative single-use Sius™ TFF technology to downstream bioprocessing portfolio

Repligen Acquires TangenX Technology Corporation

Repligen Acquires TangenX Technology Corporation

Adds innovative single-use Sius™ TFF technology to downstream bioprocessing portfolio

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

These stocks are down some 20% over the last 30 months and look ripe for a rise.

Repligen is Now Oversold (RGEN)

Repligen is Now Oversold (RGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Repligen (RGEN) Shares Cross Below 200 DMA

Repligen (RGEN) Shares Cross Below 200 DMA

In trading on Thursday, shares of Repligen Corp. crossed below their 200 day moving average of $27.23, changing hands as low as $26.59 per share.

Repligen Reports Third Quarter 2016 Financial Results

Repligen Reports Third Quarter 2016 Financial Results

Third quarter 2016 revenue of $24.7 million reflects 25% year-over-year growth

Repligen To Report Third Quarter 2016 Financial Results

Repligen To Report Third Quarter 2016 Financial Results

Webcast and Conference Call to Be Held Thursday, November 3, 8:30 a.m. ET

TheStreet Quant Rating: B- (Buy)